Idiopathic granulomatous myositis

Summary

Idiopathic granulomatous myositis (MONDO:0002644) is a disease. A subtype of myositis disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	idiopathic granulomatous myositis
Mondo ID	MONDO:0002644
Orphanet	206979
DOID	DOID:3428
NCIT	C27575
UMLS	C1334150
MedGen	235204
GARD	0023202
Is cancer (heuristic)	no

Also known as: idiopathic granulomatous myositis

Disease family

This is a subtype of myositis disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › myopathy › myositis disease › idiopathic granulomatous myositis

Related subtypes (10): myositis ossificans, tendinitis, myositis fibrosa, inclusion body myositis, viral myositis, bacterial myositis, fungal myositis, infectious myositis, orbital myositis, idiopathic inflammatory myopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.